Gilead Sciences is responding to a World Health Organization (WHO) report that its experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China.

A WHO spokesperson confirmed to FOX Business that the report was shared early and taken down.

"We believe the post included inappropriate characterizations of the study. The study was terminated early due to low enrollment and, as a result, it was underpowered to enable statistically meaningful conclusions," according to a Gilead statement.."As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease."

While there are some legitimate medical researchers in China, right now, I think it's reasonable to dismiss any research coming out of Chine related to infectious diseases. The researchers are not free to communicate the real results or procedural details of any research they have conducted.